Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 258

1.

[Hepatitis C virus: 25 years-old, the end?].

Pol S.

Med Sci (Paris). 2013 Nov;29(11):998-1003. doi: 10.1051/medsci/20132911016. Epub 2013 Nov 20. Review. French.

PMID:
24280503
[PubMed - indexed for MEDLINE]
2.

Rapid progression of antiviral treatments of chronic hepatitis C virus infection.

Pol S, Corouge M, Mallet V, Sogni P.

Minerva Gastroenterol Dietol. 2013 Jun;59(2):161-72.

PMID:
23831907
[PubMed - indexed for MEDLINE]
3.

[Treatment of hepatitis C: current status and perspectives].

Pol S, Corouge M.

Rev Prat. 2014 May;64(5):605-12. French.

PMID:
24923038
[PubMed - indexed for MEDLINE]
4.

Treatment of hepatitis C virus genotype 3-infection.

Pol S, Vallet-Pichard A, Corouge M.

Liver Int. 2014 Feb;34 Suppl 1:18-23. doi: 10.1111/liv.12405. Review.

PMID:
24373074
[PubMed - indexed for MEDLINE]
5.

Triple therapy with first generation HCV protease inhibitors: lead-in or no lead-in phase?

Pascale A, Serfaty L.

J Hepatol. 2013 Feb;58(2):391-4. doi: 10.1016/j.jhep.2012.09.023. Epub 2012 Oct 9.

PMID:
23063419
[PubMed - indexed for MEDLINE]
Free Article
6.

New treatments for chronic hepatitis C virus infection.

Corouge M, Pol S.

Med Mal Infect. 2011 Nov;41(11):579-87. doi: 10.1016/j.medmal.2011.04.003. Epub 2011 Jul 20. Review.

PMID:
21764234
[PubMed - indexed for MEDLINE]
7.

Antiviral strategies in hepatitis C virus infection.

Sarrazin C, Hézode C, Zeuzem S, Pawlotsky JM.

J Hepatol. 2012;56 Suppl 1:S88-100. doi: 10.1016/S0168-8278(12)60010-5. Review.

PMID:
22300469
[PubMed - indexed for MEDLINE]
8.

Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir.

Hofmann WP, Chung TL, Osbahr C, Susser S, Karey U, Mihm U, Welsch C, Lötsch J, Sarrazin C, Zeuzem S, Herrmann E.

Antivir Ther. 2011;16(5):695-704. doi: 10.3851/IMP1821.

PMID:
21817191
[PubMed - indexed for MEDLINE]
9.

New direct-acting antivirals' combination for the treatment of chronic hepatitis C.

Asselah T, Marcellin P.

Liver Int. 2011 Jan;31 Suppl 1:68-77. doi: 10.1111/j.1478-3231.2010.02411.x. Review.

PMID:
21205141
[PubMed - indexed for MEDLINE]
10.

[Israeli guidelines for the treatment of chronic hepatitis C infection--2012 Israeli Association for the Study of the Liver].

Zuckerman E, Safadi R, Oren R, Shibolet O, Baruch Y, Bruck R, Lurei Y, Kaspa RT, Abu-Mouch S, Shouval D, Ben-Ari Z; Israeli Association for the Study of the Liver.

Harefuah. 2012 Dec;151(12):709-14, 719. Hebrew.

PMID:
23330266
[PubMed - indexed for MEDLINE]
11.

A new era in the treatment of chronic hepatitis C infection.

Jothimani D, Chandy GM, Conjeevaram H.

Indian J Gastroenterol. 2013 Mar;32(2):71-9. doi: 10.1007/s12664-012-0254-5. Epub 2012 Sep 28. Review.

PMID:
23054947
[PubMed - indexed for MEDLINE]
12.

Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C.

Perry CM.

Drugs. 2012 Mar 26;72(5):619-41. doi: 10.2165/11208370-000000000-00000. Review.

PMID:
22439668
[PubMed - indexed for MEDLINE]
13.

The role of resistance in HCV treatment.

Vermehren J, Sarrazin C.

Best Pract Res Clin Gastroenterol. 2012 Aug;26(4):487-503. doi: 10.1016/j.bpg.2012.09.011. Review.

PMID:
23199507
[PubMed - indexed for MEDLINE]
14.

Boceprevir: a protease inhibitor for the treatment of hepatitis C.

Chang MH, Gordon LA, Fung HB.

Clin Ther. 2012 Oct;34(10):2021-38. doi: 10.1016/j.clinthera.2012.08.009. Epub 2012 Sep 11. Review.

PMID:
22975763
[PubMed - indexed for MEDLINE]
15.

Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.

Chan K, Lai MN, Groessl EJ, Hanchate AD, Wong JB, Clark JA, Asch SM, Gifford AL, Ho SB.

Clin Gastroenterol Hepatol. 2013 Nov;11(11):1503-10. doi: 10.1016/j.cgh.2013.05.014. Epub 2013 May 22.

PMID:
23707354
[PubMed - indexed for MEDLINE]
16.

Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.

Manns MP, Markova AA, Calle Serrano B, Cornberg M.

Liver Int. 2012 Feb;32 Suppl 1:27-31. doi: 10.1111/j.1478-3231.2011.02725.x. Review.

PMID:
22212568
[PubMed - indexed for MEDLINE]
17.

Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders.

Chayama K, Takahashi S, Toyota J, Karino Y, Ikeda K, Ishikawa H, Watanabe H, McPhee F, Hughes E, Kumada H.

Hepatology. 2012 Mar;55(3):742-8. doi: 10.1002/hep.24724. Epub 2012 Jan 30.

PMID:
21987462
[PubMed - indexed for MEDLINE]
18.

Treatment failure with new hepatitis C drugs.

Soriano V, Vispo E, Poveda E, Labarga P, Barreiro P.

Expert Opin Pharmacother. 2012 Feb;13(3):313-23. doi: 10.1517/14656566.2012.653341. Epub 2012 Jan 14. Review.

PMID:
22242928
[PubMed - indexed for MEDLINE]
19.

[Direct antiviral treatment strategies in chronic hepatitis C].

Neumann-Haefelin C, Blum HE, Thimme R.

Dtsch Med Wochenschr. 2012 Jun;137(25-26):1360-5. doi: 10.1055/s-0032-1305064. Epub 2012 May 31. Review. German.

PMID:
22653493
[PubMed - indexed for MEDLINE]
20.

Hepatitis C protease and polymerase inhibitors in development.

Liu-Young G, Kozal MJ.

AIDS Patient Care STDS. 2008 Jun;22(6):449-57. doi: 10.1089/apc.2007.0199. Review.

PMID:
18479202
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk